secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-06-16T12:46:01+00:00
Accession:  0001104659-26-074346
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts resubmitted BLA for Outlook's ONS-5010; PDUFA date July 29, 2026
----------------------------------------------------------------------------

- FDA acknowledged receipt of resubmitted BLA for ONS-5010 (bevacizumab-vikg) to treat wet AMD.
- Class 1 review with 60-day review period; PDUFA target action date set for July 29, 2026.
- If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with standardized manufacturing & labeling.
- Company has initiated pre-launch activities in anticipation of potential BLA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/0001104659-26-074346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-074346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer